Research
Hormonal
Blood pressure targets for most nonpregnant adults with T2DM should be <130/80 mmHg, with stricter targets (<1.8 mmol/L LDL-C) for those with atherosclerotic cardiovascular disease.
Manage your blood pressure to below 130/80 mmHg. If you have heart disease, aim for even lower LDL cholesterol (<1.8 mmol/L). This integrated control is crucial for preventing heart and stroke complications.
WeakSupportsHIGH confidence
For most nonpregnant adults with T2DM, reasonable control targets include HbA1c <7%, blood pressure < 130/80 mmHg, LDL-C < 2.6 mmol/L (without atherosclerotic cardiovascular disease (ASCVD)) or <1.8 mmol/L (with ASCVD), and BMI < 24 kg/m2.
Why this rating
Based on multiple clinical trials and meta-analyses cited in the guideline.
Source
Standards of medical care for type 2 diabetes in China 2019
Weiping Jia et al. · Diabetes/Metabolism Research and Reviews · 2019
DOI 10.1002/dmrr.3158
clinical_guidelineCited 758×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle interventions, specifically moderate-intensity physical activity for at least 150 minutes per week and caloric restriction, significantly reduce the risk of developing type 2 diabetes in individuals with prediabetes.Weak
- Metformin is the preferred first-line pharmacological monotherapy for type 2 diabetes, to be continued unless contraindicated.Weak
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →